Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors.

about

Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors.

Item

http://www.wikidata.org/entity/Q47095218

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Design, Synthesis, and Evaluat ...... FR Tyrosine Kinase Inhibitors.

@en

Design, Synthesis, and Evaluat ...... FR Tyrosine Kinase Inhibitors.

@nl

type

Item

label

Design, Synthesis, and Evaluat ...... FR Tyrosine Kinase Inhibitors.

@en

Design, Synthesis, and Evaluat ...... FR Tyrosine Kinase Inhibitors.

@nl

prefLabel

Design, Synthesis, and Evaluat ...... FR Tyrosine Kinase Inhibitors.

@en

Design, Synthesis, and Evaluat ...... FR Tyrosine Kinase Inhibitors.

@nl

P1476

Design, Synthesis, and Evaluat ...... GFR Tyrosine Kinase Inhibitors

@en

P2093

Disha Wang

http://www.w3.org/2001/XMLSchema#string

Hua Xie

http://www.w3.org/2001/XMLSchema#string

Lili Zhu

http://www.w3.org/2001/XMLSchema#string

Linjiang Tong

http://www.w3.org/2001/XMLSchema#string

Shiliang Li

http://www.w3.org/2001/XMLSchema#string

Xia Wang

http://www.w3.org/2001/XMLSchema#string

Xiuqin Hu

http://www.w3.org/2001/XMLSchema#string

Yi Tong

http://www.w3.org/2001/XMLSchema#string

Yufang Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

P304

101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FCHEM.2017.00101

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

You Yang

P577

2017-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29250520

http://www.w3.org/2001/XMLSchema#string

P932

5715404

http://www.w3.org/2001/XMLSchema#string